Trials / Unknown
UnknownNCT05799443
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer: a Phase II, Single-arm Study
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 23 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of SBRT followed by tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced refractory colorectal cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tislelizumab | Tislelizumab will be administered on day 1 of each cycle at 200mg once every 14 days. |
| DRUG | Irinotecan Hydrochloride | Irinotecan will be administered on day 1 of each cycle at 180 mg/m2 once every 14 days. |
| DRUG | cetuximab | cetuximab will be administered on day 1 of each cycle at 500 mg/m2 once every 14 days. |
| RADIATION | SBRT | 8-10Gy×5F，QOD |
Timeline
- Start date
- 2023-04-05
- Primary completion
- 2024-04-05
- Completion
- 2025-04-05
- First posted
- 2023-04-05
- Last updated
- 2023-04-05
Source: ClinicalTrials.gov record NCT05799443. Inclusion in this directory is not an endorsement.